Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical...
Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately...
Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have...
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable...
SHANGHAI, July 25, 2025 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development,...
Olympus co-founds Swan EndoSurgical with Revival Healthcare Capital
Olympus to take a significant equity stake in Swan EndoSurgical with a combined initial investment of...
- International Conference of the Modernization of Chinese Medicine & Health Products to be held next month to foster progress in traditional medicine research
-...
